Regeneron’s COVID-19 Antibody Cocktail Shows Early Promise, But Does It Merit An EUA?
Could Help Patients Who Lack Own Antibody Response
Serology tests found around 40% of trial patients had generated no antibodies against the disease - making them higher risk, and more likely to benefit from REGN-COV2.
